## FACTS FROM PFIZER'S COURT DOCUMENTS AND RULING IN THE WHISTLEBLOWER CASE: BROOK JACKSON V. VENTAVIA-PFIZER FOR FALSE CLAIMS

The following facts are from Pfizer's April 22, 2022

Motion to Dismiss and testimony delivered to the

Texas Senate Health and Human Services and

House Public Health Committees on

March 22, 2023.

- Pfizer's "Other Transaction Authority (OTA)"
   agreement was signed with the United States
   Department of Defense (DoD) in July of 2020 and
   <u>Fosun, a Chinese CCP conglomerate</u>.
- The OTA is not subject to standard "Federal Acquisition Regulations."
- 3. COVID-19 vaccine manufacturers are immune from all liability as military countermeasures and are not subject to drug regulations.
- 4. The Statement of Work is to provide a COVID-19 "large-scale vaccine manufacturing demonstration", that "imposes no requirements relating to Good Clinical Practices (GCP) or FDA Regulations", and "Pfizer's 'clinical trials' are 'out of scope' and 'not related' to the agreement."
- 5. The OTA agreement included "Operation Warp Speed, to purchase the first 100 million doses for \$19.50 per dose."
- 6. The case was dismissed on March 31, 2023, on pg 33, "if the Government pays a particular claim in full despite its actual knowledge that certain requirements were violated ... 'not material'."

  <u>USDC ED Texas Beaumont / Judge Truncale</u>

NOTE: The only requirement of product efficacy is a statement from the HHS Secretary that a product "may be effective." 21 USC 360bbb-3(c)(2)(A)

Per Federal laws, State public health policies are preempted by HHS and neither the courts can have judicial review, nor does Congress has the authority to review or revoke the unilateral power and decision of the HHS Secretary to dictate actions during a declared "Public Health Emergency of International Concern."

42 USC 247d-6d(b)(7-9)